No 02 2018

The company has been granted a patent by the European Patent Office (EPO) for GmPcides, a new class of synthetic antibacterials.

This collaboration aims to advance the discovery and development of new therapeutic solutions targeting G protein-coupled receptors (GPCRs), ion channels, transporters and other integral membrane proteins in therapeutic areas such as mental health and cardio-renal-metabolic diseases.

Cellevate has appointed Christel Fenge as Chief Technology Officer (CTO) and member of the management team.

The 5th Nordic RWE and AI Conference, January 28-29 2025 in Helsinki, brought together around 300 participants from the pharmaceutical industry, technical data solution providers, consultancy firms, universities, healthcare providers, and the health authorities.

Professor Kirsi Pietiläinen, Professor of Clinical Metabolism at the Faculty of Medicine, University of Helsinki, receives the prize for her outstanding work in clinical metabolism.

This decision by the Board of Directors of Peptonic Medical is an extraordinary measure following a prolonged liquidity challenge and is intended to create the conditions for a stable and profitable business, they state.

The company has received positive and constructive feedback for its lead drug product PN6047, a selective delta opioid receptor agonist, from the U.S. Food and Drug Administration (FDA).